Thalidomide-5-NH2-C8-NH2 TFA may be utilized in the preparation /synthesis of compounds.

Physicochemical Properties

Molecular Formula	C23H29F3N4O6
Molecular Weight	514.49477648735
Exact Mass	514.203
CAS #	2097509-49-2
PubChem CID	132260585
Appearance	Light yellow to green yellow solid powder
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	10
Heavy Atom Count	36
Complexity	722
Defined Atom Stereocenter Count	0
SMILES	FC(C(=O)O)(F)F.O=C1C2C=C(C=CC=2C(N1C1C(NC(CC1)=O)=O)=O)NCCCCCCCCN
InChi Key	NVUSVLWAQSTODF-UHFFFAOYSA-N
InChi Code	InChI=1S/C21H28N4O4.C2HF3O2/c22-11-5-3-1-2-4-6-12-23-14-7-8-15-16(13-14)21(29)25(20(15)28)17-9-10-18(26)24-19(17)27;3-2(4,5)1(6)7/h7-8,13,17,23H,1-6,9-12,22H2,(H,24,26,27);(H,6,7)
Chemical Name	5-(8-aminooctylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;2,2,2-trifluoroacetic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Michael Bruno Plewe, et al. Compounds and methods of treating diseases. Patent WO2022068933A1.

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (194.37 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.9437 mL	9.7184 mL	19.4367 mL
	5 mM	0.3887 mL	1.9437 mL	3.8873 mL
	10 mM	0.1944 mL	0.9718 mL	1.9437 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.